BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21897229)

  • 1. The cardioprotective effects of metformin.
    El Messaoudi S; Rongen GA; de Boer RA; Riksen NP
    Curr Opin Lipidol; 2011 Dec; 22(6):445-53. PubMed ID: 21897229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metformin and left ventricular remodeling after acute myocardial infarction: molecular mechanisms and clinical implications].
    Paneni F; Costantino S; Cosentino F
    G Ital Cardiol (Rome); 2015 Apr; 16(4):225-31. PubMed ID: 25959758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling.
    Calvert JW; Gundewar S; Jha S; Greer JJ; Bestermann WH; Tian R; Lefer DJ
    Diabetes; 2008 Mar; 57(3):696-705. PubMed ID: 18083782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin improves cardiac function in rats via activation of AMP-activated protein kinase.
    Wang XF; Zhang JY; Li L; Zhao XY; Tao HL; Zhang L
    Clin Exp Pharmacol Physiol; 2011 Feb; 38(2):94-101. PubMed ID: 21143620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection with pioglitazone is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts--comparison of the effects of pioglitazone and metformin.
    Kawabata H; Ishikawa K
    Diabetes Metab Res Rev; 2003; 19(4):299-305. PubMed ID: 12879407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of metformin on myocardial tolerance to ischemia in rats with diabetes mellitus type 2].
    Kravchuk EN; Grineva EN; Galagudza MM; Bairamov AA
    Patol Fiziol Eksp Ter; 2013; (4):32-4. PubMed ID: 24640771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular effects of metformin: lost in translation?
    Riksen NP; Tack CJ
    Curr Opin Lipidol; 2014 Dec; 25(6):446-51. PubMed ID: 25255478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin therapy in diabetes: the role of cardioprotection.
    El Messaoudi S; Rongen GA; Riksen NP
    Curr Atheroscler Rep; 2013 Apr; 15(4):314. PubMed ID: 23423523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury.
    Simpkin JC; Yellon DM; Davidson SM; Lim SY; Wynne AM; Smith CC
    Basic Res Cardiol; 2007 Nov; 102(6):518-28. PubMed ID: 17694254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction.
    Varjabedian L; Bourji M; Pourafkari L; Nader ND
    Am J Cardiovasc Drugs; 2018 Jun; 18(3):181-193. PubMed ID: 29478240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon.
    Whittington HJ; Hall AR; McLaughlin CP; Hausenloy DJ; Yellon DM; Mocanu MM
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):5-16. PubMed ID: 23192487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that hydroxysafflor yellow A protects the heart against ischaemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening.
    Liu YN; Zhou ZM; Chen P
    Clin Exp Pharmacol Physiol; 2008 Feb; 35(2):211-6. PubMed ID: 17941891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cardioprotective effects of mineralocorticoid receptor antagonists.
    van den Berg TN; Rongen GA; Fröhlich GM; Deinum J; Hausenloy DJ; Riksen NP
    Pharmacol Ther; 2014 Apr; 142(1):72-87. PubMed ID: 24275323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin: ready for prime-time cardioprotection.
    Riksen NP; Hausenloy DJ; Yellon DM
    Trends Pharmacol Sci; 2008 May; 29(5):258-67. PubMed ID: 18359096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of adenosine as adjunctive therapy in acute myocardial infarction.
    Forman MB; Stone GW; Jackson EK
    Cardiovasc Drug Rev; 2006; 24(2):116-47. PubMed ID: 16961725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway.
    Ueda K; Takano H; Hasegawa H; Niitsuma Y; Qin Y; Ohtsuka M; Komuro I
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):e108-13. PubMed ID: 16574892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts.
    Balakumar P; Singh H; Reddy K; Anand-Srivastava MB
    J Cardiovasc Pharmacol; 2009 Sep; 54(3):204-12. PubMed ID: 19568176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMGB1: the missing link between diabetes mellitus and heart failure.
    Volz HC; Seidel C; Laohachewin D; Kaya Z; Müller OJ; Pleger ST; Lasitschka F; Bianchi ME; Remppis A; Bierhaus A; Katus HA; Andrassy M
    Basic Res Cardiol; 2010 Nov; 105(6):805-20. PubMed ID: 20703492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Met5-enkephalin-Arg6-Phe7 (MEAP): a cardioprotective hormonal opioid.
    Dickson EW; Ludwig PS; Ackermann LW; Buresh CT; Denning GM
    Acad Emerg Med; 2006 Aug; 13(8):813-9. PubMed ID: 16766738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.